scholarly journals Vascular Endothelial Growth Factor is an Autocrine Growth Factor for Cardiac Myxoma Cells

2004 ◽  
Vol 68 (5) ◽  
pp. 488-493 ◽  
Author(s):  
Hironosuke Sakamoto ◽  
Tetsuo Sakamaki ◽  
Tsugiyasu Kanda ◽  
Yoko Tsuchiya ◽  
Mahito Sato ◽  
...  
Blood ◽  
2001 ◽  
Vol 98 (6) ◽  
pp. 1904-1913 ◽  
Author(s):  
Rizwan Masood ◽  
Jie Cai ◽  
Tong Zheng ◽  
D. Lynne Smith ◽  
David R. Hinton ◽  
...  

Abstract Angiogenesis is required for the progression of tumors from a benign to a malignant phenotype and for metastasis. Malignant tumor cells secrete factors such as vascular endothelial growth factor (VEGF), which bind to their cognate receptors on endothelial cells to induce angiogenesis. Here it is shown that several tumor types express VEGF receptors (VEGFRs) and that inhibition of VEGF (VEGF antisense oligonucleotide AS-3) or VEGFRs (neutralizing antibodies) inhibited the proliferation of these cell lines in vitro. Furthermore, this effect was abrogated by exogenous VEGF. Thus, VEGF is an autocrine growth factor for tumor cell lines that express VEGFRs. A modified form of VEGF AS-3 (AS-3m), in which flanking 4 nucleotides were substituted with 2-O-methylnucleosides (mixed backbone oligonucleotides), retained specificity and was active when given orally or systemically in vitro and in murine tumor models. In VEGFR-2–expressing tumors, VEGF inhibition may have dual functions: direct inhibition of tumor cell growth and inhibition of angiogenesis.


2001 ◽  
Vol 193 (4) ◽  
pp. 468-475 ◽  
Author(s):  
Luigi Strizzi ◽  
Alfonso Catalano ◽  
Giovina Vianale ◽  
Sara Orecchia ◽  
Angelo Casalini ◽  
...  

1996 ◽  
Vol 106 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Souad Lachgar ◽  
Hafida Moukadiri ◽  
Frédéric Jonca ◽  
Marie Charveron ◽  
Nadia Bouhaddioui ◽  
...  

2000 ◽  
Vol 119 (1) ◽  
pp. 101-107 ◽  
Author(s):  
Tetsuya Kono ◽  
Naohiko Koide ◽  
Yoshiyuki Hama ◽  
Hiroto Kitahara ◽  
Hirohumi Nakano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document